Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ZYMOGENETICS INC (ZGEN)
|
Add to portfolio |
|
|
|
| Price: |
$24.18
| | Metrics |
| OS: |
85.9
|
M
| |
-2
|
% ROE
|
| Market cap: |
$2.08
|
B
| |
9
|
% ROIC
|
|
Net cash:
|
$206
|
M
| |
$2.40
|
per share
|
|
EV:
|
$1.87
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$13.6
|
M
| |
137.9
|
x EV/EBITDA
|
|
EBIT
|
$7.2
|
M
| |
259.5
|
x EV/EBIT
|
| EPS |
($0.04)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| Revenues | 137.0 | 74.0 | 38.5 | 25.4 | 42.9 | 35.7 | 26.0 | 52.8 |
| Revenue growth | 85.1% | 92.3% | 51.6% | -40.9% | 20.2% | 37.5% | -50.8% | 196.0% |
| Cost of goods sold | 7.6 | 5.7 | 142.3 | 128.5 | 47.8 | 51.2 | 18.0 | 14.8 |
| Gross profit | 129.3 | 68.3 | -103.9 | -103.1 | -4.9 | -15.5 | 7.9 | 38.0 |
| Gross margin | 94.4% | 92.3% | -269.9% | -406.1% | -11.4% | -43.4% | 30.5% | 71.9% |
| Selling, general and administrative | 62.2 | 60.2 | 46.9 | 33.2 | 23.3 | | 104.4 | 104.2 |
| Research and development | | | | | 24.5 | 27.7 | 18.0 | 14.8 |
| General and administrative | | | | | | 23.5 | | |
| EBIT | -32.1 | -118.6 | -150.8 | -136.3 | -80.0 | -86.9 | -60.4 | -36.6 |
| EBIT margin | -23.4% | -160.3% | -391.8% | -537.0% | -186.5% | -243.4% | -232.7% | -69.4% |
| Pre-tax income | -43.3 | -116.2 | -148.1 | -130.0 | -78.0 | -88.8 | -59.6 | -30.3 |
| Income taxes | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -43.0 | -116.2 | -148.1 | -130.0 | -78.0 | -88.8 | -59.6 | -32.1 |
| Net margin | -31.4% | -157.1% | -385.0% | -512.2% | -181.8% | -248.7% | -229.5% | -60.8% |
| |
| Diluted EPS | ($0.62) | ($1.69) | ($2.17) | ($1.94) | ($1.28) | ($1.64) | ($1.26) | ($0.75) |
| Shares outstanding (diluted) | 69.1 | 68.7 | 68.2 | 66.9 | 60.9 | 54.2 | 47.3 | 42.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|